share_log

Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In...

Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In...

辉瑞表示,将在2024年第二季度启动一项多年度计划,以降低我们的商品销售成本;降低商品销售成本的多年计划的第一阶段预计将在2027年底之前节省约15亿美元;成本将主要记录在...
Benzinga ·  05/23 00:43

Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In 2024, With Cash Outlays Expected In 2025 And 2026; One-Time Costs To Achieve Savings Associated With First Phase Of Program Are Expected To Be About $1.7B

辉瑞表示,将在2024年第二季度启动一项多年度计划,以降低我们的商品销售成本;降低商品销售成本的多年计划的第一阶段预计将在2027年底之前节省约15亿美元;成本将主要记录在2024年,现金支出预计在2025年和2026年;实现与第一阶段计划相关的节省的一次性成本预计约为17亿美元

- Reuters

-路透社

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发